Abstract |
Inflammation is a physiologic response to damage triggered by infection, injury or chemical irritation. Chronic inflammation produces repeated damage to cells and tissues, which can induce a variety of human diseases including cancer. Verteporfin, an FDA approved drug, is used for the treatment of age-related macular degeneration. The anti- tumor effects of verteporfin have been demonstrated by a number of studies. However, fewer studies focus on the anti-inflammatory functions of this drug. In this study, we investigated the anti-inflammatory effects and potential mechanisms of verteporfin. The classic lipopolysaccharide (LPS)-induced inflammation cell model was used. RAW 264.7 cells were pre-treated with verteporfin or vehicle control, followed by LPS stimulation. Verteporfin inhibited IL-6 and TNF-α at mRNA and protein expression levels. This effect was mediated through inhibition of the NF-κB and JAK/STAT pathways. Finally, verteporfin exhibited an anti- inflammation effect by crosslinking of protein such as NF-κB p65, JAK1, JAK2, STAT1, or STAT3 leading to inflammation. Taken together, these results indicate that verteporfin has the potential to be an effective therapeutic agent against inflammatory diseases.
|
Authors | Yuting Wang, Lei Wang, James T F Wise, Xianglin Shi, Zhimin Chen |
Journal | Toxicology and applied pharmacology
(Toxicol Appl Pharmacol)
Vol. 387
Pg. 114852
(01 15 2020)
ISSN: 1096-0333 [Electronic] United States |
PMID | 31812773
(Publication Type: Journal Article)
|
Copyright | Copyright © 2019 Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Inflammation Mediators
- Lipopolysaccharides
- Verteporfin
|
Topics |
- Animals
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Humans
- Inflammation
(drug therapy, immunology)
- Inflammation Mediators
(immunology, metabolism)
- Lipopolysaccharides
(immunology)
- Macrophages
(drug effects, immunology, metabolism)
- Mice
- RAW 264.7 Cells
- Signal Transduction
(drug effects, immunology)
- Verteporfin
(pharmacology, therapeutic use)
|